Digest Network Come funziona
Network
/
Società
Ra
Non verificato

Ray Therapeutics

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOtticaSalute

7 comunicati stampa

Guarda tutti i comunicati
29/04/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Ottica
Ray Therapeutics Granted Priority Medicines (PRIME) Designation from the European Medicines Agency for RTx-015 in Retinitis Pigmentosa
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
21/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Ottica
Medicina - Varie
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Biotecnologia
Igiene alimentare
Sanità
Salute
Ottica
Scienza
Medicina - Varie
Ray Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RTx-015 in Retinitis Pigmentosa
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
17/02/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Ray Therapeutics Appoints Michael Murtagh as Chief Regulatory Officer
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
08/01/2026
Mercato del lavoro
Biotecnologia
Ottica
Salute
Medicina - Varie
Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
24/04/2025
Mercato del lavoro
Industria
Scienza
Biotecnologia
Medicina - Varie
Biologia
Farmaceutica
Salute
Ottica
Ray Therapeutics Awarded $8M CIRM Grant to Advance RTx-015 Gene Therapy for Retinitis Pigmentosa
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0
16/09/2024
Ray Therapeutics Appoints Christopher Whitmore as Chief Financial Officer
Fonte
Ray Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0